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 Racial and ethnic differences in therapeutic response to pharmacotherapy 
were raised in the field of heart failure (HF) just over 2 decades ago by the results of 
the Vasodilator-Heart Failure Trials (V-HeFT) trials. V-HeFT I demonstrated that 
Hydralazine-Isosorbide (H-I) therapy resulted in significant reductions in mortality 
in African Americans compared to placebo, but not in Caucasians (1). The follow-up 
study V-HeFT II confirmed these results and further demonstrated that ACEI were of 
greater benefit in Caucasians (2). Based on these results, African-American Heart 
Failure Trial (A-HeFT) trial was designed to study the effects on clinical outcomes of 
the fixed combination of isosorbide dinitrate plus hydralazine to standard therapy 
in African American patients with heart failure.  It demonstrated that isosorbide 
dinitrate plus hydralazine increased survival and improved symptoms. These 
results lead to the FDA approval of a HF therapy in a specific racial group (3). H-I is 
currently recommended for all black patients with NYHA Class III-IV Heart failure in 
addition to optimal medical therapy and for all patients with heart failure who are 
intolerant of ACEI/ARB (4). 
 In this issue of the Journal, Eshtehardi P et al. (5) attempts to further 
delineate our understanding of the racial/ethnic difference in the treatment of heart 
failure. In this retrospective, multi-center propensity score matched study of 618 
patients with heart failure with reduced ejection fraction (HFrEF) the authors 
evaluated the effect of ACEI therapy on all cause-mortality and heart failure 
hospitalizations between 3 racial/ethnic groups, Hispanics, Caucasians and African 
Americans. The study included patients who self identified racial/ethnic group, 
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were of similar socioeconomic background, had EF < 35% and were all on beta 
blocker therapy therapy.   
After the authors performed propensity score matching and stratified by 
racial/ethnic group they observed a distinct benefit from ACEI use in Hispanics. In 
Caucasian and African American patients ACEI use was associated with a non-
significant reduction in all cause mortality, 9.2% vs 10.3% and 12.4% vs 17.8% for 
ACEI vs No-ACEI respectively. However in Hispanics the use of ACEI therapy 
resulted in a surprising 67% reduction in all cause-mortality (9.8% vs. 28.4%; HR: 
0.033, p = 0.018). 
 Before discussing the impact of the manuscript by Eshtehardi P et al on the 
understanding and management of heart failure in Hispanic patients, it will be 
important to summarize the existent data of heart failure in Hispanics. 
Hispanics represent the fastest growing racial/ethnic group in the US, yet are 
largely underrepresented in clinical trials. The Hispanic population is a 
heterogeneous group that is identified by a common language, yet from widely 
different geographical regions. In the US the Hispanic population includes people of 
European (Spain), Caribbean, Central and South American ancestry. Although it is 
unclear if there are significant differences between Hispanics of different geographic 
ancestry, unobserved or unknown differences in this heterogeneous population may 
affect the response to HF therapies. Hispanics carry a high burden of CV risk factors, 
often higher than other racial/ethnic groups. Diabetes mellitus, obesity, tobacco use, 
uncontrolled BP (6), dyslipidemia and metabolic syndrome are more prevalent in 
the Hispanic population (7). The Hispanic population also suffers unique barriers to 
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health care including language, lack of health insurance, acculturation and cultural 
beliefs.   
 Data from Get With the Guidelines – Heart Failure registry (GWTG-HF) (8) 
and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients 
with Heart Failure (OPTIMIZE-HF) (9) demonstrated racial/ethnic disparities with 
regard to heart failure performance measures. Hispanics are less likely to have 
assessment of left ventricular function (10), less likely to be prescribed ACEI/ARB at 
discharge and are less likely to receive complete discharge instructions. These 
discrepancies highlight the significant need for strategies to improve the care 
provided to Hispanics with HF. In addition, a study of 561 patients with heart failure 
from a Heart Failure Disease Management Program (Jackson Medical Hospital in 
Miami, Florida) demonstrated that Hispanics patients with heart failure and systolic 
dysfunction had an 82% use of ACE inhibitors (21 % on target doses) and an 89% 
use of beta-blockers (21 % on target doses) (11). The percentage of Hispanics 
adhering to the medication increased by the second appointment, but decreased 
discretely at the next follow up visits. While ACEI use was relatively high in 
Hispanics they were less likely to achieve target doses for the ACEI/ARB when 
compared to African Americans (12).  
Despite the limitations, the paper by Eshtehardi P et al in the Journal is of interest as 
it provides data on clinical outcomes utilizing life saving heart failure therapies in an 
Hispanic population 
However, these results must be tempered because of several limitations of the data 
and the design of the study. 
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First, the reduction in mortality was significantly greater than the one observed in 
the landmark Studies of Left Ventricular Dysfunction (SOLVD) (13) and Cooperative 
North Scandinavian Enalapril Survival Study (CONSENSUS) (14) trials, which were 
done prior to the era of Guideline Directed Medical Therapy (GDMT), 16% and 27% 
reduction respectively.  
In both landmark trials the reduction in mortality was driven by reductions in 
mortality due to progression of heart failure, whereas these data showed a decrease 
in all cause mortality.  The limitations of the study design did not allow for 
adjudication of CV or HF deaths, which must be taken into consideration. The lack of 
difference in hospitalizations for heart failure may be a clue to the fact that these 
patients did not die from heart failure. Furthermore the cohort of patients 
prescribed ACEI may represent a population of patients that were more compliant, 
routinely followed with health care professionals and ultimately received better 
management of other contributing comorbid conditions. Of note, the mortality rate 
in the untreated Hispanic cohort was significantly higher compared with the 
untreated white and African American patients, 28.4% vs. 10.3% and 17%, 
respectively, suggesting the Hispanic population in this study were at significantly 
higher risk, possibly due to differences in background guideline therapies.   
Second, in the era of modern medicine, a placebo controlled randomized trial 
of ACEI therapy would be unethical. As such the use of propensity score matching is 
a reasonable alternative, however limitations remain. Propensity score matching 
can reduce the number of confounders and control for some baseline differences, 
unfortunately initial selection bias cannot be eliminated. Furthermore variables not 
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included in the propensity score may still affect the outcome and other unseen 
variables may bias the results.  As a result of the retrospective analysis the authors 
were unable to assess outcomes based on ACEI dose or compliance. The use of other 
HF therapies such as mineralocorticoid receptor antagonists (MRA), which have 
been shown to be prescribed more commonly in Hispanics (8), cardiac 
resynchronization therapy (CRT) or digoxin were also not studied.  While the 
authors included diabetes, one of the strongest predictors for outcome in HF, body-
mass-index (BMI) was not included. In the Candesartan in Heart Failure – 
Assessment of Mortality and Morbidity (CHARM) trial (15), BMI was a strong 
predictor of outcome in HF patients and obesity is a prevalent CV risk factor in the 
Hispanic population.  
   Interestingly upon performing multivariate analysis in the matched 
population ACEI use was found to be an independent predictor of lower all-cause 
mortality in only Hispanics (HR: 0.33, p = 0.018), conversely a physician 
documented NYHA Functional class III / IV was an independent predictor of higher 
mortality in Hispanics (HR: 2.99, p = 0.04). It is unclear why NYHA Class was not a 
predictor of mortality in Caucasians and African Americans. In an analysis of the 
CHARM trial NYHA Class was a strong predictor of CV death and hospitalization, 
which included almost exclusively Caucasian and African American patients (15). 
This lack of effect in Caucasians and African Americans may be a result of difference 
in background therapy, in the CHARM trial slightly more than 50% of patients were 
on a beta-blocker, where as in this study all patients were required to be on BB. The 
propensity score matched data did not demonstrate an improvement in hospital 
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admissions in this trial even in the Hispanic cohort. Interestingly recent data from 
the GWTG-HF program seems to contradicts these findings, in the GWTG-HF 
population Hispanics had higher readmission rates and lower mortality compared 
with Caucasians with heart failure, and similar to African American patients (16). 
The in GTWG-HF population the higher readmission rates could be attributed to 
fewer Hispanic patients receiving complete discharge instructions, resulting in 
lower compliance with dietary restrictions and adherence to medical therapy. 
However the lower mortality in Hispanics in the GTWG-HF population was present 
even in the setting of lower ACEI use.  
 Upon reading this paper the question one asks is simple; does this change 
our management? Fundamentally the answer must be no. The authors have shown 
once again that ACEI therapy improves outcome in patients with heart failure, 
whether ACEIs preferentially benefit Hispanics with heart failure remains to be 
determined. The data presented here should remind us that all patients benefit from 
GDMT, while some may benefit more than others from certain therapies, our 
responsibility is to ensure that all patients receive optimal medical therapy and seek 
to eliminate disparities in our practice and in the use of evidence based therapies. 
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